logo
  

GVC Confirms Proposal To Bwin.party At 122.5 Pence Per Share

GVC Holdings Plc. (GVC.L) Monday confirmed that it has made a proposal to the Board of bwin.party digital entertainment Plc. (BPTY.L) for the acquisition of the entire issued and to be issued share capital of bwin.party.

As per the offer, bwin.party shareholders would be entitled to receive 122.5 pence for each bwin.party share, consisting of up to 25 pence in cash, and the balance of the value in new GVC ordinary shares.

bwin.party also confirmed that it has received a revised indicative proposal to acquire all outstanding and to be issued share capital of bwin.party with an indicative valuation of up to 122.5 pence per bwin.party share, comprised of up to 25 pence in cash and the balance in new GVC shares.

GVC said it would finance the proposal via a combination of the issuance of new GVC shares, to bwin.party shareholders, and a 400 million euros senior secured loan provided by affiliates of Cerberus Capital Management, L.P.

In addition, the company intends to raise about 150 million pounds through an equity placing of new GVC shares for cash to fund restructuring costs, the refinancing of existing bwin.party debt and for additional working capital purposes.

If a transaction were to be completed, the GVC Board believes that cost reductions exceeding 135 million euros per annum would be achieved across the enlarged group by the end of 2017.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT